scorecardresearch
Zydus gets tentative nod from USFDA to market diabetic tablets

Zydus gets tentative nod from USFDA to market diabetic tablets

According to IT company IMS health, the estimated sales in 2014 for Glipizide ER tablets is US $90.1 million, the company said in a BSE filing.

Photo for representation purposes only. (Source: Reuters) Photo for representation purposes only. (Source: Reuters)

Drug firm Zydus Cadila has received a tentative nod from the health regulator USFDA to market Glipizide tablets, used for treatment of diabetes, in America.

"Zydus Cadila has received tentative approval from the United States Food and Drug Administration (USFDA) to market Glipizide extended release tablets in the strengths of 2.5 mg, 5 mg and 10 mg," Zydus group's listed entity, Cadila Healthcare, said in a filing to the Bombay Stock Exchange (BSE).

According to IT company IMS health, the estimated sales in 2014 for Glipizide ER tablets is US $90.1 million, it added.

"The group now has 97 approvals and has so far filed 249 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-2004," Cadila Healthcare said.

Shares of Cadila Healthcare were trading at Rs 1,291.20 per scrip, up points (or 0.30 per cent) in the afternoon on the BSE.